GLP-1 News & Analysis
5 articles
Market Mood
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More
GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
Over 600,000 prescriptions for Novo Nordisk's Wegovy (NVO) were written by February 2023, indicating increased demand for weight loss drugs. Currently, nearly 13% of U.S. adults are on a GLP-1 medication, with adoption rates increasing from 11% in November 2024 to 16% in November 2025. Retailers are reporting a rise in customers seeking new clothing due to weight loss, with specific interest noted by services like Stitch Fix. Analysts predict that as accessibility improves, consumer spending on apparel is expected to grow significantly, particularly for smaller sizes.
Read More
GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
GoodRx (GDRX) has announced that it will offer the Foundayo GLP-1 medication starting at a price of $149 per month. This move provides a lower-cost option for patients seeking weight management treatments. The availability of this medication may impact the market for weight-loss pharmaceuticals by introducing competition. As healthcare costs continue to be a focus for consumers and providers, this pricing could influence purchasing decisions in the sector.
Read More
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More